ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 123 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $117,090 | +2.3% | 5,837 | +43.9% | 0.01% | +25.0% |
| Q2 2023 | $114,448 | +80.8% | 4,057 | +10.2% | 0.00% | +33.3% |
| Q1 2023 | $63,313 | -25.2% | 3,681 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $84,626 | +7.1% | 3,681 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $79,000 | +2.6% | 3,681 | +33.8% | 0.00% | +33.3% |
| Q2 2022 | $77,000 | -39.4% | 2,752 | 0.0% | 0.00% | -40.0% |
| Q1 2022 | $127,000 | -45.0% | 2,752 | 0.0% | 0.01% | -37.5% |
| Q4 2021 | $231,000 | +26.2% | 2,752 | 0.0% | 0.01% | +14.3% |
| Q3 2021 | $183,000 | +31.7% | 2,752 | +5.6% | 0.01% | +40.0% |
| Q2 2021 | $139,000 | +33.7% | 2,607 | +8.3% | 0.01% | +25.0% |
| Q1 2021 | $104,000 | -16.8% | 2,408 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $125,000 | +316.7% | 2,408 | +163.7% | 0.01% | +500.0% |
| Q3 2020 | $30,000 | -31.8% | 913 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $44,000 | – | 913 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |